GLP-1 Market and Competitive Landscape

Comprehensive coverage of GLP-1 receptor agonist market dynamics, including Eli Lilly's portfolio (Zepbound, Mounjaro), competitive positioning against Novo Nordisk, clinical efficacy comparisons, pipeline developments, regulatory considerations, and market expansion into obesity, diabetes, and other therapeutic areas.

Tirzepatide's $85B Rise Hinges on Asia-Pacific Access

Lilly's dual-incretin leads a consolidated market, yet APAC access remains uncertain.

By KAPUALabs

/ 21 Jul 2026

Lilly's GLP-1 Bet: Explosive Upside, Concentrated Risk

Tirzepatide fuels 80% revenue surge even as two-thirds of sales concentrate in one therapy.

By KAPUALabs

/ 21 Jul 2026

Lilly's Obesity Bet Pays Off Amid Constraints

Zepbound's 80% revenue jump signals upside, but access and supply cap the bull case.

By KAPUALabs

/ 21 Jul 2026

GLP-1 Market Signals Lilly Edge, Not Valuation Proof

Structural peptide demand favors Lilly, but peer data falls short of valuation proof.

By KAPUALabs

/ 20 Jul 2026

Lilly's Obesity Platform Enters a Multi-Route Growth Phase

Oral GLP-1 and global filings signal a platform shift beyond injectable franchises.

By KAPUALabs

/ 20 Jul 2026

GLP-1 Supremacy Now Hinges on China Manufacturing and Trade

China's biotech rise and local manufacturing now define global GLP-1 competitive advantage.

By KAPUALabs

/ 20 Jul 2026

Lilly's Bull Case Rides Tirzepatide, Bear Case Warns Concentration

Tirzepatide's $12.8B quarter fuels upside but concentrates Lilly's revenue and risk exposure.

By KAPUALabs

/ 20 Jul 2026

Lilly Leads GLP-1 Race as Novo and Price Risk Loom

Lilly leads on efficacy and oral reach, but Novo and pricing loom large.

By KAPUALabs

/ 20 Jul 2026

Lilly's Tirzepatide: Bull Run Faces Concentration Risk

Tirzepatide powers two-thirds of revenue and global share gains, yet concentration risk persists.

By KAPUALabs

/ 20 Jul 2026

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Decoded

A comprehensive assessment of clinical efficacy, manufacturing scalability, and PBM dynamics shaping the metabolic market.

By KAPUALabs

/ 19 Jun 2026

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Decoded

The Alchemy of GLP-1: How Eli Lilly Formulated a Therapeutic Revolution

From tirzepatide's surgical-level weight loss to oral orforglipron, a story of systematic advantage.

By KAPUALabs

/ 19 Jun 2026

The Alchemy of GLP-1: How Eli Lilly Formulated a Therapeutic Revolution

Semaglutide vs Tirzepatide: A Formulation-Based Clinical Assessment

Comprehensive analysis of efficacy, safety, and commercial implications for obesity treatment market.

By KAPUALabs

/ 19 Jun 2026